Trial Profile
Phase I Study to Evaluate the Safety of Neratinib in Combination With Paclitaxel, Trastuzumab and Pertuzumab in Women and Men With Advanced or Metastatic HER2+ Solid Tumors
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Neratinib (Primary) ; Paclitaxel; Pertuzumab; Trastuzumab
- Indications Solid tumours
- Focus Adverse reactions
- 13 Nov 2017 Status changed from recruiting to discontinued.
- 04 Nov 2015 New trial record